Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-100IT in Acute Spinal Cord Injury
NCT02193334Phase 2Completed
- Sponsor
- Kringle Pharma, Inc.
- Start
- Jun 2014
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of KP-100 in spinal cord injury (SCI), sponsored by Kringle Pharma, Inc.. Started Jun 2014; status: completed.
02
Drugs
KP-100
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02193334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193334.